Drug Profile
BMS 986120
Alternative Names: BMS986120Latest Information Update: 29 Sep 2021
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Imidazoles; Small molecules; Thiadiazoles
- Mechanism of Action Proteinase-activated receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 29 Sep 2021 Discontinued - Phase-I for Thrombosis (In volunteers) in United Kingdom (PO) (Bristol-Myers Squibb pipeline, September 2021)
- 29 Sep 2021 Discontinued - Phase-II for Thrombosis in USA (PO) (Bristol-Myers Squibb pipeline, September 2021)
- 28 Oct 2018 No recent reports of development identified for phase-I development in Thrombosis(In volunteers) in United Kingdom (PO)